Safety Tolerability footer references

In the amivantamab/lazertinib arm, the median OS in the Asian population was not reached vs 38.4 months in the osimertinib arm for patients with EGFR-mutated NSCLC.

Daniel C. McFarland, DO, and Charles S. Kamen, PhD, MPH, focused on cultural humility, nonverbal data collection, and tailored resources to improve care.

The FDA approved pirtobrutinib as a treatment for patients with CLL/SLL who received prior BTK inhibition based on the phase 3 BRUIN-CLL-321 trial results.

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

Linvoseltamab monotherapy achieved minimal residual disease negativity in 95% of patients with newly diagnosed multiple myeloma.

More than half of evaluable patients in the phase 1/2 NEXICART-2 trial experienced organ responses following treatment with NXC-201.